Date | Price Target | Rating | Analyst |
---|---|---|---|
6/29/2023 | $2.00 | Mkt Perform → Outperform | Barrington Research |
12/15/2022 | $3.00 | Buy | H.C. Wainwright |
1/24/2022 | Outperform → Market Perform | Barrington Research |
SC 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)
SC 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)
SC 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)
Enhances Labcorp's laboratory services network and expands access to its clinical services BURLINGTON, N.C. and MIAMI, Sept. 16, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company, announced today the completion of Labcorp's acquisition of select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. The transaction is expected to provide patients, physicians and customers with greater access to Labcorp's comprehensive, high-quality laboratory services, scientific expertise and expanded testing capabilities in key regions a
JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended June 30, 2024. "We continue to deliver strong execution with key milestones achieved during the second quarter of 2024 across each of our N-Tab™ oral peptide programs dedicated to patients with OBGYN/endocrinology, GI and metabolic diseases," said Miranda Toledano, Entera's CEO. "Importantly, we are now just five months away from FDA's potential landmark ruling on the ASBMR-FNIH SABRE regulatory endpoint for osteoporosi
MIAMI, Aug. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three and six months ended June 30, 2024. Highlights from the second quarter and recent weeks include the following: Enrollment underway in the MDX2001 Phase 1 trial for the treatment of solid tumor cancers. MDX2001, a tetraspecific antibody, is designed to optimize T-cell function to stimulate tumor regression while minimizing the likelihood of antigen escape. This Phase 1 open-label trial is expected to enroll 45 cancer patients with a variety of solid tumors at six clinical trial sites, and to evaluate safety, tolerability, pharmacokinetics and early eviden
8-K - OPKO HEALTH, INC. (0000944809) (Filer)
DEFR14A - OPKO HEALTH, INC. (0000944809) (Filer)
10-Q - OPKO HEALTH, INC. (0000944809) (Filer)
NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Shareholders of Talkspace, Inc. (NASDAQ:TALK) today elected Jon Cohen, M.D., to the virtual behavioral healthcare company's board of directors and approved all other shareholder proposals during the company's first Annual Meeting of Stockholders. Dr. Cohen is prior Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President of OPKO Health (NASDAQ:OPK). Dr. Cohen brings 30 years of healthcare industry strategy and operating experience to Talkspace's board of directors. He succeeds Jeffrey Crowe as an independent Class I Director with a term expiring in 2025. Additionally, the Company's board appointed C
MIAMI, June 22, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., the global genomics subsidiary of OPKO's BioReference Laboratories. Ms. Stueland joins GeneDx from Invitae Corporation (NYSE:NVTA), where she served most recently as Chief Commercial Officer, establishing the corporate brand as Invitae evolved from a private company to a public entity with a market capitalization exceeding $6 billion. "We're thrilled to have Katherine lead the team at GeneDx, which has served clinicians and patients for more than two decades with novel and differentiated technologies for di
BOTHELL, Wash., May 28, 2021 (GLOBE NEWSWIRE) -- With great sadness, Cocrystal Pharma, Inc. (NASDAQ:COCP), ("Cocrystal" or the "Company") announces that Gary Wilcox, Ph.D., Chairman, CEO and co-founder, suddenly passed away Wednesday, May 26 at the age of 74. The Board of Directors and staff of Cocrystal extend their deepest condolences to the Wilcox family and express their gratitude for Gary's contributions to Cocrystal and to human health. The Cocrystal Board of Directors has designated Sam Lee, Ph.D., President, and James Martin, CFO, to share the CEO responsibilities while seeking a successor for the position. Roger Kornberg, Ph.D., Cocrystal co-founder, Chief Scientist, Director and
Barrington Research upgraded Opko Health from Mkt Perform to Outperform and set a new price target of $2.00
H.C. Wainwright initiated coverage of Opko Health with a rating of Buy and set a new price target of $3.00
Barrington Research downgraded OPKO Health from Outperform to Market Perform
4 - OPKO HEALTH, INC. (0000944809) (Reporting)
4 - OPKO HEALTH, INC. (0000944809) (Issuer)
4 - OPKO HEALTH, INC. (0000944809) (Issuer)
Opko Health, Inc. (NASDAQ:OPK) shares are trading higher Thursday after the company announced a $100 million share repurchase program. The Details: Opko said it expects to fund the repurchase program from existing cash and cash equivalents, and future cash flows. The company had approximately 697 million shares outstanding as of June 30, 2024, and the new authorization represents approximately 10.1% of shares outstanding at the current stock price. Read Next: Discover Reports Better-Than-Expected Q2 Results: Here’s The Details “We believe OPKO’s shares are significantly undervalued and offer an attractive investment opportunity. Buying back shares supports our conviction in OPKO’
U.S. stocks were higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Cintas Corporation (NASDAQ:CTAS) rose during Thursday's session after the company reported better-than-expected quarterly EPS and revenues. Cintas reported fourth-quarter earnings per share of $3.99, beating the street view of $3.80. The company registered quarterly revenues of $2.471 billion, beating the street view of $2.468 billion, according to data from Benzinga Pro. Cintas shares gained 5.3% to $758.25 on Thursday. Here are some other big stocks recording gains in today’s session. Chuy’s Holdings, Inc. (NASDAQ:CHUY) shares gained 47.6% to $37.29 after the company and Darde
4 - OPKO HEALTH, INC. (0000944809) (Issuer)
4 - OPKO HEALTH, INC. (0000944809) (Issuer)
4 - OPKO HEALTH, INC. (0000944809) (Issuer)
MIAMI, Aug. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three and six months ended June 30, 2024. Highlights from the second quarter and recent weeks include the following: Enrollment underway in the MDX2001 Phase 1 trial for the treatment of solid tumor cancers. MDX2001, a tetraspecific antibody, is designed to optimize T-cell function to stimulate tumor regression while minimizing the likelihood of antigen escape. This Phase 1 open-label trial is expected to enroll 45 cancer patients with a variety of solid tumors at six clinical trial sites, and to evaluate safety, tolerability, pharmacokinetics and early eviden
MIAMI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three and six months ended June 30, 2024 after the close of the U.S. financial markets on Wednesday, August 7, 2024. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on August 7th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Part
MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business highlights include the following: Entered into an agreement with Labcorp to sell select assets of BioReference Health. The transaction includes the sale of BioReference Health's laboratory testing businesses focused on clinical diagnostics and women's health, excluding operations in New York and New Jersey, for $237.5 million. These assets comprise patient service centers, certain customer contracts and operating assets, which account for approximately $100 million in annualized revenue. BioReference Hea